Of the papers screened for eligibility, tamoxifen use was only included in a single model, Kitson et al. [48], which consists of a total score calculated by combining obesity, reproductive, insulin, and genetic sub-scores. The gene discussed is INS; the disease is obesity due to melanocortin 4 receptor deficiency.